Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy

Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy

Abstract Background Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment for several mature B-cell malignancies. Reactivation of hepatitis B virus (HBV) is a well-described complication in patients with chronic HBV infection or prior HBV exposure undergoing cytotoxic or...

Full description

Bibliographic Details
Main Authors: Lok-Ka Lam, Thomas Sau Yan Chan, Yu-Yan Hwang, Lung-Yi Mak, Wai-Kay Seto, Yok-Lam Kwong, Man-Fung Yuen
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Virology Journal
Subjects:
HBV reactivation
Ibrutinib
B cell depletion
Occult hepatitis B
Case report
Online Access:https://doi.org/10.1186/s12985-023-02140-w

Internet

https://doi.org/10.1186/s12985-023-02140-w

Similar Items